O6-ALKYLGUANINE-DNA ALKYLTRANSFERASE INACTIVATORS AND BETA-GLUCURONIDASE CLEAVABLE PRODRUGS
申请人:MOSCHEL C. Robert
公开号:US20070213279A1
公开(公告)日:2007-09-13
Disclosed are prodrugs of inactivators of O
6
-alkylguanine-DNA alkyltransferase (AGT). The prodrugs are cleavable by the β-glucuronidase enzyme, which is either administered to the patient or produced by necrotic tumor cells. The prodrugs are represented by the formula A-B-C, wherein A is a glucuronosyl residue linked through its 1-oxygen to the phenyl ring of B; B is a benzyloxycarbonyl group, optionally ring-substituted with one or more electron withdrawing groups; and C is an inactivator of AGT, e.g., a substituted or unsubstituted O
6
-benzylguanine or O
6
-benzyl-2′-deoxyguanosine, Also disclosed are additional inactivators of AGT, pharmaceutical compositions comprising an inactivator or prodrug and a pharmaceutically acceptable carrier, and a method of use of the inactivator or prodrug in enhancing the chemotherapeutic treatment of tumor cells in a mammal, e.g., a human, with an antineoplastic alkylating agent that causes cytotoxic lesions at the O
6
-position of guanine.
本发明公开了O6-烷基鸟嘌呤-DNA烷基转移酶(AGT)不活化剂的前药。这些前药可被β-葡萄糖醛酸酶酶水解,该酶可由患者口服或由坏死的肿瘤细胞产生。该前药的化学式为A-B-C,其中A是葡萄糖醛酸残基,通过其1-氧原子与B的苯环连接;B是苄氧羰基基团,可选地带有一个或多个电子吸引基;C是AGT的不活化剂,例如取代或未取代的O6-苄基鸟嘌呤或O6-苄基-2'-脱氧鸟苷。本发明还公开了其他AGT不活化剂、包含不活化剂或前药及其药学可接受载体的制药组合物,以及在使用抗肿瘤烷基化剂在哺乳动物(例如人类)中增强肿瘤细胞的化疗治疗中使用不活化剂或前药的方法。